Elicio files historical financials of Private Elicio post-merger; Q1 net loss $8.0M, going concern flagged

Elicio Therapeutics, Inc.

Private Elicio net loss of $8.0M for Q1 2023; accumulated deficit $115.0M at March 31, 2023.
Cash and equivalents of $8.6M at March 31, 2023; negative operating cash flow of $8.1M in Q1.
Auditor's going concern opinion citing losses, negative cash flows, and need for additional financing.
Merger with Angion closed June 1, 2023; company renamed Elicio Therapeutics, now trading as ELTX.
Pro forma combined financials filed; no revenue for Private Elicio in the periods presented.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.